Amylyx hosts investor event to discuss Phase 3 avexitide results

AMLX•2026-11-04

Amylyx Pharmaceuticals will host an investor event at ObesityWeek in Washington, D.C., on November 15, 2026, to review Phase 3 LUCIDITY results for avexitide.

1. Event details

The in-person and virtual event is scheduled for 11:45 a.m. ET. Trial investigators Marilyn Tan and Zeb Saeed will discuss the disease burden of post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.

Amylyx hosts investor event to discuss Phase 3 avexitide results

1. Event details

Related News

Guided Therapeutics provides update on its cervical cancer screening study with Türkiye’s Ministry of Health

Par Pacific forecasts 2026 capital spending and turnaround costs of $190 million-$220 million

Immunome's IM-1021 shows 53% response rate in early-stage B-cell lymphoma trial

Marzetti publishes fiscal 2027 first-quarter earnings call transcript

Voyager awarded $35M contract to manage NASA HUNCH